EGFR and cancer: Such situations may arise during the development of HPV(+) cancers that have mutations in PIK3CA (or downstream effectors) and/or become refractory to EGFR or PI3K inhibitors, which we and others reported can lead to MEK/ERK stimulation via other RTKs [84–87].